Carmona-Rocha, E, Rusiñol, L, Puig, L. Erosive Lesions in the Legs of an Elderly Woman. INDIAN JOURNAL OF DERMATOLOGY. 2025; 70(1)DOI:10.4103/ijd.ijd_851_23. PMID:39896302. IF:1.300(Q3/7D).

Dauden, E, Ortiz-Salvador, JM, Notario, J, Puig, L, Santos-Juanes, J, Herrera-Acosta, E, Gomez-Labrador, L, Ruiz-Villaverde, R. Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review. Journal of Clinical Medicine. 2025; 14(2)DOI:10.3390/jcm14020478. PMID:39860484. IF:2.900(Q1/2D).

Hernández, G, Martin, M, Alonso, S, Romero, I, Salvado, N, Farrés, M, Osuna, C, Bustínduy, M, de Araníbar, JG, Manresa, M, Velasco, M, Ferrer, A, Riesco, M, Genao, D, Ruíz-Villaverde, R, Boquete, L, Martínez, C, Rull, E, Descalzo, MA. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.05.022. PMID:38876209. IF:(Q/D).

Hernández, GC, Martín, MA, Alonso, SA, Romero, IB, Salvado, NE, Farrés, MF, Osuna, CG, Bustínduy, MG, de Aranibar, JGL, Manresa, MJ, Velasco, ML, Ferrer, AL, Riesco, MR, Genao, DR, Ruíz-Villaverde, R, Boquete, LS, Martínez, CS, Rull, EV, Descalzo, MA. Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.10.009. PMID:. IF:(Q/D).

Mateu-Arrom, L, Puig, L. Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy. Psoriasis-Targets And Therapy. 2025; 15DOI:10.2147/PTT.S510141. PMID:40237012. IF:(Q/D).

Girolomoni, G, Feldman, SR, Egeberg, A, Puig, L, Jung, J, Jung, H, Lee, Y. Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). JOURNAL OF DERMATOLOGICAL TREATMENT. 2024; 35(1)DOI:10.1080/09546634.2024.2434091. PMID:39626886. IF:3.900(Q1/2D).

Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londono, A, Lebwohl, M, Nash, P. Safety in patients with latent tuberculosis who received concomitant anti-tuberculosis medications: analysis of 11 studies of guselkumab in psoriatic disease. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.098. PMID:. IF:9.600(Q1/1D).

Maul, JT, Bonnekoh, B, Puig, L, McKenzie, R, Lampropoulou, A, Martimianaki, G, Fotiou, K, Pinter, A, Akiror, C. Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.093. PMID:. IF:9.600(Q1/1D).

Gatica-Ortega, ME, Pastor-Nieto, MA, Giménez-Arnau, AM, Mercader-García, P, Serra-Baldrich, E, Zaragoza-Ninet, V, Sanz-Sánchez, T, Sánchez-Gilo, A, Pesqué, D, Tous-Romero, F, Ortiz-de-Frutos, FJ, de la Rosa-Fernández, E, Dorta-Alom, S, Elosua-González, M, Gonzalez-Perez, R, Carrascosa-Carrillo, JM, Munera-Campos, M, Silvestre-Salvador, JF, Miquel-Miquel, J, Minguez, AD, Borrego, L. An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1). CONTACT DERMATITIS. 2024; 91(5)DOI:10.1111/cod.14675. PMID:39164011. IF:4.600(Q1/1D).

Frutos, JOD, Baldrich, ES, Boixareu, MJT, Hita, JCA, Carrillo, JMC, Nart, IF, Flórez, A, Pinto, PH, Silvestre, JF. [Translated article] Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2024.09.011. PMID:39260612. IF:(Q/D).

Ferrer, AL, Romero, IB, Díaz, RR, Pinto, PH. Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2023.05.044. PMID:39033804. IF:(Q/D).

de Frutos, JO, Baldrich, ES, Boixareu, MJT, Hita, JCA, Carrillo, JMC, Nart, IF, Menéndez, AF, Pinto, PH, Silvestre, JF. Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2024.03.035. PMID:38663729. IF:(Q/D).

Chicharro, P, Munera-Campos, M, Zaragoza-Ninet, V, Giménez-Arnau, A, González-Pérez, R, Miquel-Miquel, FJ, Córdoba-Guijarro, S, Sanz-Sánchez, T, Ruiz-González, I, Silvestre-Salvador, JF, Serra-Baldrich, E, Borrego, L, Pastor-Nieto, MA, de Frutos, FJO, Mercader-García, P, Heras-Mendaza, F, Fernández-Redondo, V, Rodríguez-Serna, M, Hervella-García, M, Carrascosa, JM, Gallego-Descalzo, MA, García-Doval, I, Sánchez-Pérez, J. Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC). CONTACT DERMATITIS. 2024; 91(5)DOI:10.1111/cod.14672. PMID:39138883. IF:4.600(Q1/1D).

Iznardo, H, Roé, E, Vicente, A, Prat, C, Casals, M, Martín-Santiago, A, Esteve, A, Viñas, M, Munera-Campos, M, Corella, F, Mollet, J, Figueras-Nart, I, Vila, A, Soria, X, Azón-Masoliver, A, Marqués-Martín, L, Nadal-Lladó, C, Bel, S, Pujol-Montcusí, J, Bertolín-Colilla, M, Curto-Barredo, L, Melé-Ninot, G, Evole, M, Berbegal, L, Puig, L, Baselga, E. Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2024; 50(1)DOI:10.1093/ced/llae300. PMID:39093288. IF:2.800(Q2/4D).

Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Ngantcha, M, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies. Expert Opinion On Drug Safety. 2024; 23(10)DOI:10.1080/14740338.2024.2399092. PMID:39234767. IF:3.100(Q2/4D).

Stolnicki, DK, Coates, LC, Gollins, CE, Koppikar, S, Perez-Chada, LM, Puig, L, Ogdie, A, Deodhar, A, Ritchlin, C, Hwang, ST, Goldenstein-Schainberg, C. Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. JOURNAL OF RHEUMATOLOGY. 2024; 51DOI:10.3899/jrheum.2024-0621. PMID:39089830. IF:3.400(Q2/3D).

Puig, L, Costanzo, A, de Jong, EMGJ, Torres, T, Warren, RB, Wapenaar, R, Wegner, S, Gorecki, P, Gramiccia, T, Jazra, M, Buyze, J, Conrad, C. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01245-6. PMID:39153060. IF:4.200(Q1/1D).

Puig, L, Belloso, RI, Rivera-Díaz, R, Sánchez, JM, Fernández-Freire, LR, Sahuquillo-Torralba, A, Ruiz-Villaverde, R. A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study. DERMATOLOGY. 2024; 240(5-6)DOI:10.1159/000540019. PMID:39019021. IF:2.700(Q2/4D).

Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Petrick, M, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londo o, A, Lebwohl, M, Nash, P. Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

Tha i, D, Puig, L, Merola, JF, Jullien, D, Costanzo, A, Wang, M, Deherder, D, Pinto, JML, Lebwohl, M. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).